| |
James A. Bristol, Ph.D.
Executive-in-Residence
Boston, MA
jbristol@oxbio.com |
James A. Bristol, an Executive-in-Residence for Oxford Bioscience Partners, recently retired following 32 years in drug discovery research at Schering-Plough, Parke-Davis, and most recently Pfizer. Jim most recently held the position of Senior Vice President, Worldwide Drug Discovery Research, Pfizer Global Research & Development (PGRD), New London, CT. In that role, he was responsible for more than 3000 scientists and colleagues at seven Pfizer sites in the U.S., U.K., and Japan,. Over the period of 2004 – 2006, WW Discovery Research scientists at Pfizer produced more than 130 drug candidates in 11 therapeutic areas. Before moving to New London, Jim was Vice President, Discovery Research, PGRD, Ann Arbor, Michigan, a position he was appointed to in May 2000. Jim joined Parke-Davis in 1980, where he held positions of increasing responsibility in the Chemistry Department and in 1992 was appointed Vice President, Chemistry. At Parke-Davis, Jim was a member of numerous collaboration oversight committees with responsibility for joint research programs run by Parke-Davis and a biopharmaceutical company. Examples include Onyx, Biochem Pharma, Neurex, CoCensys, BASF, LeukoSite, Aurora, and others. Prior to Joining Parke-Davis in 1980, Jim spent six years in the Chemistry Department at Schering-Plough Corporation.
Regarding drug discovery and development activities, Jim has been interested in establishing ways and means to improve the efficiency and effectiveness of discovery and preclinical development, including the early evaluation, adoption and integration of new enabling technologies. He is also interested in adapting sound business principles to the discovery and development of drugs. One example is discovery portfolio analysis, strategy and planning - a worldwide function that Jim established at Pfizer.
Jim's research interests have included published work in drug discovery programs related to the treatment of gastrointestinal diseases, CNS diseases, and cardiovascular diseases which have been recorded in over 100 publications, abstracts, and patents. Professional activities have included officer positions in the ACS Division of Medicinal Chemistry (Secretary, Vice Chairman, Chairman), several ACS committee assignments, and the Board of Trustees of the Gordon Research Conferences, Vice Chairman and Chairman of the Gordon Conference on Medicinal Chemistry, Keystone Conference co-Chair, Adjunct Professor of Medicinal Chemistry at the University of Michigan, and numerous invited lectureships. Jim was Editor in Chief of the ACS publication series, Annual Reports in Medicinal Chemistry for 9 years.
Jim received his Ph.D. in organic chemistry from the University of New Hampshire in 1972 and his B.S. in chemistry from Bates College in 1968. He conducted postdoctoral research at the University of Michigan (N.I.H. Postdoctoral Fellow) from 1972-73, and at The Squibb Institute for Medical Research from 1973-74.
Back to OBP Team
|
|